A phase II clinical study assessing TQS-168
Latest Information Update: 07 Jun 2022
At a glance
- Drugs TQS 168 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Therapeutic Use
- Sponsors Tranquis Therapeutics
- 03 Jun 2022 According to Tranquis Therapeutics media release, this study is planned to initiate by end of year 2022
- 14 Dec 2021 New trial record
- 08 Dec 2021 According to Tranquis Therapeutics media release, this trial will move into clinic in the near-term.